Treatment Options for Triple-Negative Breast Cancer

Metastatic TNBC: First-Line Treatment Algorithm

The National Comprehensive Cancer Network recommends albumin-bound paclitaxel plus carboplatin as the superior combination regimen for metastatic triple-negative breast cancer, demonstrating significantly longer progression-free survival (8.3 months) and overall survival (16.8 months) compared to other doublet combinations, with an impressive 73% objective response rate 1
The American Society of Clinical Oncology suggests atezolizumab plus nab-paclitaxel as the preferred regimen for PD-L1-positive disease, achieving median overall survival of 25 months versus 15.5 months with chemotherapy alone (HR 0.62) 2
For patients with CPS ≥10, pembrolizumab plus chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) is an alternative treatment option 3

The National Comprehensive Cancer Network recommends pembrolizumab plus taxane-carboplatin-anthracycline-cyclophosphamide as the category 1 recommendation for stage II-III TNBC, with benefit independent of PD-L1 status 2
The European Society for Medical Oncology notes that the evidence for adding carboplatin to neoadjuvant regimens is mixed and does not translate to improved survival outcomes 6

The American Society of Clinical Oncology strongly prefers PARP inhibitors (olaparib or talazoparib) over chemotherapy for BRCA-mutated TNBC, with 40-60% improvement in progression-free survival 5
The National Comprehensive Cancer Network strongly recommends sacituzumab govitecan after ≥2 prior therapies, demonstrating dramatic superiority with an ORR of 35% vs 5% with chemotherapy 4

The National Comprehensive Cancer Network recommends germline BRCA1/2 mutation testing for all TNBC patients to identify PARP inhibitor candidates 2
The American Society of Clinical Oncology recommends PD-L1 testing (≥1% tumor-infiltrating immune cells for atezolizumab; CPS ≥10 for pembrolizumab) to guide immunotherapy decisions 3